Rituxan (rituximab) / Zenyaku Holdings, Biogen, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

170 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
RiVa, NCT03307746: A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma

Active, not recruiting
2a
26
Europe
Varlilumab, Rituximab
University Hospital Southampton NHS Foundation Trust, University Hospital Plymouth NHS Trust, The Christie NHS Foundation Trust, Oxford University Hospitals NHS Trust, Celldex Therapeutics, Cancer Research UK
B Cell Lymphoma
02/21
03/24
2012-001597-29: Tumor uptake of ofatumumab and rituximab, labeled with 89Zirconium, in patients with malignant lymphoma. Tumor opname van ofatumumab en rituximab, gelabeld met 89Zirconium bij patienten met lymfeklierkanker

Ongoing
2
45
Europe
rituximab-N-succinyl-desferal-zirconium-89, ofatumumab-N-succinyl-desferal-zirconium-89, 89Zr-rituximab, 89Zr-ofatumumab, Solution for injection/infusion
VU University Medical Center, VU University Medical Center, GlaxoSmithKline
Diffuse large B cell lymphoma (DLBCL), lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
CALGB-50403, NCT00310037: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Active, not recruiting
2
151
US
bortezomib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc.
Mantle Cell Lymphoma
12/13
 
NCT01472562: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
38
US
lenalidomide, revlimid, rituximab, rituxan
Weill Medical College of Cornell University, Celgene
Mantle Cell Lymphoma
04/14
07/23
NCT01199575: Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
2
30
US
Revlimid, lenalidomide, Rituximab, Rituxan
University of California, San Diego, Celgene Corporation
Chronic Lymphocytic Leukemia, CLL
01/15
02/22
2014-005069-60: R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) as first line therapy for elderly patients with diffuse-large B cell lymphoma (DLBCL) and for patients with limited cardiac function with DLBCL R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) als Erstlinientherapie für ältere Patienten mit diffus großzelligem B-Zell-Lymphom (DLBCL) und für Patienten mit eingeschränkter Herzfunktion mit DLBCL

Ongoing
2
60
Europe
Powder for concentrate for solution for infusion, Pixuvri®
Medical Center - University of Freiburg, Servier Affaires Médicales, CTI Life Sciences Limited
Diffuse-large B cell lymphoma (DLBCL), A subtype of non-Hodgkin lymphoma, a tumour disease involving B lymphocytes, a particular type of white blood cells with a key role in immune system, Diseases [C] - Cancer [C04]
 
 
NCT01027000: Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
2
68
US
rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Genentech, Inc., Biologics, Inc.
Leukemia, Lymphoma
01/16
04/23
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Active, not recruiting
2
140
Europe
cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2
Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories
Primary Central Nervous System Lymphoma
05/16
05/26
2015-003371-29: Phase II study. A combination of Lenalidomide and Rituximab as front line therapy for elderly frail patients (CGA) with Diffuse Large B-cells non-Hodgkin Lymphoma. Studio di fase II per valutare la combinazione di Lenalidomide e Rituximab in prima linea nei pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili (CGA)

Not yet recruiting
2
68
Europe
Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 20 mg, [IMP1], [IMP2], [IMP3], [IMP4], Capsule, hard, REVLIMID - 5 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CASPULE, REVLIMID - 10 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 20 MG- CAPSULA RIGIDA- USO ORALE- BLISTER (PCTFE/PVC/ALU)- 21 CAPSULE
FONDAZIONE ITALIANA LINFOMI ONLUS, Celgene
Diffuse Large B-cells non-Hodgkin Lymphoma Linfoma diffuso a grandi cellule B, Elderly frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma. Pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2015-005454-35: An early phase study using a response based combination therapy of rituxumab and ibrutinib in patients with post-transplant lymphoproliferative disorder (PTLD)

Ongoing
2
60
Europe
Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone, Vincristine, Capsule, hard, Infusion, Oral solution, Imbruvica, MabThera, Myocet, Prednisolone
University of Birmingham, Bloodwise, Janssen
Post-transplant lymphoproliferative disorder, Post-transplant lymphoproliferative disorder, Diseases [C] - Cancer [C04]
 
 
LEGEND, NCT02060656 / 2012-002620-32: Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma

Active, not recruiting
2
92
Europe
Gemcitabine, Methylprednisolone, Rituximab, Cisplatin, Lenalidomide
Royal Marsden NHS Foundation Trust, Celgene Corporation
Diffuse Large B-Cell Lymphoma
02/18
08/23
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare

Not yet recruiting
2
130
Europe
Venclyxto, Film-coated tablet, Venclyxto
Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l.
Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-004401-40: A trial of CHOP-R therapy with or without acalabrutinib in patients with newly diagnosed Richter's Syndrome

Not yet recruiting
2
105
Europe
Cyclophosphamide, Acalabrutinib, Doxorubicin, Vincristine, Prednisolone, Rituximab, ACP-196, Powder and solvent for solution for injection/infusion, Capsule, hard, Concentrate and solvent for solution for infusion, Solution for injection, Tablet, Solution for infusion, Cyclophosphamide, Acalabrutinib, Vincristine, Prednisolone, Rituximab
University of Birmingham, Bloodwise, Acerta
Richter's Syndrome, A rare type of non-hodgkin lymphoma, Diseases [C] - Cancer [C04]
 
 
2017-005137-23: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with (ABC) DLBCLat intermediate-high and high risk Terapia R-CHOP in combinazione con ibrutinib e successivo mantenimento con ibrutinib in pazienti non trattati con linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto.

Not yet recruiting
2
90
Europe
Ibrutinib, IMP1, Capsule, hard, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (120 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen-Cilag S.p.A
Activated-B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk (IPI =2) Linfoma diffuso a grandi cellule B con profilo ABC (Activated-B-Cell) e rischio intermedio/alto o alto (IPI = 2), B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk Linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-003483-32: BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation.

Not yet recruiting
2
35
Europe
blinatumomab, blinatumomab, Concentrate for solution for injection/infusion, BLINCYTO
FILO, AMGEN
Richter transformation, Richter transformation, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2014-005493-11: Study the action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets, assuming that a definitive action upon CSF biological targets would be strongly predictive of a delayed clinical action in patients with Progressive Multiple Sclerosis. Montrer qu'un médicament (le Rituximab) injecté dans le liquide céphalo-rachidien (on parle alors d'injection intrathécale) a un effet majeur sur des marqueurs biologiques impliqués dans le processus responsable du handicap dans la forme progressive de la SEP.

Not yet recruiting
2
12
Europe
méthylprednisolone, rituximab, Powder for infusion, Solution for injection, Solution for infusion, Méthylprednisolone Mylan, Mabthera
Centre Hospitalier de Pau, Centre Hospitalier de Pau, Ministère de la Santé
Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone. Patients atteints de sclérose en plaques secondairement progressive recevant un traitement par rituximab intrathécal et intraveineux sous couvert de méthylprednisolone intraveineuse., Patients in the progressive phase of multiple sclerosis will received drugs combining venous and intrathecal infusions. Drugs were already used in both ways. Traitement de patients atteints de sclérose en plaques progressive par un médicament administré en perfusion et par ponction lombaire., Diseases [C] - Nervous System Diseases [C10]
 
 
GELTAMO-IMCL-2015, NCT02682641 / 2015-004158-17: Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Active, not recruiting
2
50
Europe
IBRUTINIB, Imbruvica, Rituximab
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.
Mantle Cell Lymphoma
12/19
12/24
2018-002364-44: Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas

Ongoing
2
175
Europe
MabThera Uso sottocutaneo, MabThera, Imbruvica, [NA], Solution for injection, Concentrate for solution for infusion, Capsule, hard, MabThera, Imbruvica
IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Previously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatment, Previously untreated marginal zone lymphoma, Diseases [C] - Cancer [C04]
 
 
2018-003560-31: Copanlisib and Standard Immuno-Chemotherapy (R-CHOP) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Copanlisib und Standard-Immunochemotherapie (R-CHOP) in Patienten mit diffusem großzelligem B-Zell-Lymphom (DLBCL)

Ongoing
2
80
Europe
Copanlisib, BAY84-1236, Lyophilisate for solution for infusion
Universitätsklinikum Münster, Bayer HealthCare Pharmaceuticals Inc.
diffuse large B-cell lymphoma diffuses großzelliges B-Zell-Lymphom, malignant disease of the lymphatic system bösartige Erkrankung des lymphatischen Systems, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-000842-36: Polatuzumab vedotin combined with standard chemo-immunotherapy drugs in diffuse large B-cell lymphoma

Not yet recruiting
2
56
Europe
Polatuzumab Vedotin, Lyophilisate for solution for infusion
The Clatterbridge Cancer Centre NHS Foundation Trust, Roche Products Ltd
Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP., A cancer of the blood affecting B-cells., Diseases [C] - Cancer [C04]
 
 
2019-003632-23: Lenalidomide and Ibrutinib in association with R-MPV first-line treatment of Primary Central Nervous System Lymphoma for patients aged 18 to 60 Lénalidomide et Ibrutinib en association avec le R-MPV en traitement d’induction de première ligne pour les patients âgés de 18 à 60 ans présentant un lymphome primitif du système nerveux central (LCP).

Not yet recruiting
2
128
Europe
Ibrutinib 140 mg, Rituximab, Methotrexate, Procarbazine, Vincristine, Prednisone, Capsule, hard, Solution for infusion, Capsule, Tablet, Revlimid 5 mg, Revlimid 10 mg, Imbruvica 140 mg
Institut Curie, PHRC-K 2018 Public Health Grant, CELGENE SAS, JANSSEN-CILAG, KEOCYT SAS
Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, en traitement de première ligne, Primary Central Nervous System Lymphoma in patients aged 18 to 60, first treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, 1er traitement, Diseases [C] - Cancer [C04]
 
 
2019-002373-59: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Eine Phase-II-Studie zur Untersuchung von Gemcitabin/Oxaliplatin/Rituximab mit Tafasitamab (MOR-00208) bei Patienten mit aggressivem Lymphom.

Ongoing
2
64
Europe
Tafasitamab, MOR00208, Lyophilisate for solution for infusion, MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
University Medical Center of the Johannes Gutenberg University Mainz, Incyte Corporation
Malignant B-cell lymphoma Aggressives B-Zell Lymphom, Malignant Lymphoma Aggressives Lymphom, Diseases [C] - Cancer [C04]
 
 
NCT00492050: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Active, not recruiting
2
46
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Rituximab, Rituxan, Valacyclovir, Valtrex
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Waldenstrom's Macroglobulinemia
02/21
06/24
2018-001850-80: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma

Not yet recruiting
2
80
Europe
acalabrutinib, Mabthera, Capsule, hard, Concentrate for solution for infusion, Mabthera
Skåne University Hospital, Nordic Lymphoma Group, Astra Zeneca
Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma (MCL), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-004409-30: Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia Trattamento con venetoclax consolidato con ibrutinib e rituximab per aumentare possibilità di malattia minima residua in paziente con leucemia linfatica cronica

Not yet recruiting
2
55
Europe
venclyxto, [venclyxto], Modified-release tablet, Venclyxto
OSPEDALE SAN RAFFAELE, AbbVie
Previously Untreated Chronic Lymphophatic Leukaemia Leucemia Linfatica Cronica non precedentemente trattata, Previously untreated low-risk blood cancer Tumore del sangue a basso rischio, non precedentemente trattato, Diseases [C] - Cancer [C04]
 
 
2021-001973-21: Extension of Study GNC-401 with temelimab in patients with Multiple Sclerosis under treatment with rituximab

Not yet recruiting
2
40
Europe
Temelimab, GNbAC1, Solution for infusion
GeNeuro Innovation SAS, GeNeuro Innovation SAS
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Active, not recruiting
2
141
Europe
Venetoclax, Venclyxto (commercial name)
Fondazione Italiana Linfomi - ETS, AbbVie
Lymphoma, Mantle-Cell
07/21
07/25
NCT04062448: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Completed
2
16
Japan
Ibrutinib, PCI-32765, Rituximab
Janssen Pharmaceutical K.K.
Waldenstrom Macroglobulinemia
08/21
03/23
PembroWM, NCT03630042 / 2018-001767-23: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Completed
2
17
Europe
Pembrolizumab, Rituximab
University College, London, Merck Sharp & Dohme LLC
Waldenstrom Macroglobulinemia
09/21
06/23
NCT03931642: BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Completed
2
41
Europe
RCHOP, Blinatumomab
French Innovative Leukemia Organisation, Amgen
Richter Syndrome
10/21
10/22
2020-004977-38: Study to determine the efficacy of Tafasitamab and lenalidomide administered in association with rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older .

Not yet recruiting
2
71
Europe
Tafasitamab, MOR208, Powder and solvent for solution for injection, Capsule, hard, Zelvina
LYSARC, Incyte
Frontline DLBCL, Diffuse Large B Cells Lymphoma, Diseases [C] - Cancer [C04]
 
 
2020-002622-87: A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemia

Not yet recruiting
2
120
Europe
Benlysta 200 mg Injektionslösung im Fertigpen, n.a., Injection, Benlysta 200 mg Injektionslösung im Fertigpen Benlysta 200 mg Injektionslösung in einer Fertigspritze
University Hospital Tuebingen, GlaxoSmithKline
Refractory or relapsed chronic lymphocytic leukemia, Refractory or relapsed chronic lymphocytic leukemia, Diseases [C] - Cancer [C04]
 
 
2019-004613-14: Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of minimal residual disease in patients with untreated chronic lymphocytic leukemia Badanie kliniczne prowadzone celem oceny skuteczności terapii kombinacją leków o nazwie wenetoklaks i rytuksymab dostosowanej do stanu minimalnej choroby resztkowej u pacjentów z do tej pory nieleczoną przewlekłą białaczką limfocytową

Not yet recruiting
2
103
Europe
Venetoclax, Rituximab, Film-coated tablet, Concentrate for solution for infusion, Venclyxto, MabThera
POLISH ADULT LEUKEMIA GROUP, AbbVie, Inc.
Chronic lymphocytic leukemia Przewlekła białaczka limfocytowa, Chronic lymphocytic leukemia is a type of tumor that affects lymphocytes and lymph nodes. In CLL, lymphocytes are produced faster and live longer, which is why their number in the blood is too large. Przewlekła białaczka limfocytowa jest rodzajem nowotworu oddziałującym na limfocyty i węzły chłonne. W PBL limfocyty są wytwarzane szybciej i żyją dłużej, dlatego ich liczba we krwi jest zbyt duża., Diseases [C] - Cancer [C04]
 
 
LYTPET, NCT00324467: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Active, not recruiting
2
150
Canada
Cyclophosphamide, Cytoxan®, Neosar®, Doxorubicin, Adriamycin ®, Rubex®, Vincristine, Oncovin ®, Vincasar Pfs ®, Vincristine Sulfate, LCR, VCR, Prednisone, Sterapred®, Sterapred® DS, Prednisone Intensol, Ondansetron, Zofran®, Zofran® ODT, Zuplenz®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Diphenhydramine, Aler-Dryl®, Benadryl®, Nytol®, Diphenhist®, Acetaminophen, Tylenol®, Ifosfamide, Ifex®, Isophosphamide, Mesna (IV), Mesnex®, Sodium 2-mercaptoethanesulfonate, Mesna (oral), Carboplatin, CBDCA, Etoposide, Etopophos®, VP-16, Rituximab, Rituxan®, PET Scan, Positron emission tomography (PET) scan
British Columbia Cancer Agency, Hoffmann-La Roche
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
12/21
12/21
2021-004864-81: Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio ORION) OBINUTUZUMAB FOR PRIMARY MEMBRANOUS NEPHROPATHY: A PILOT STUDY IN PATIENTS WITH RITUXIMAB-RESISTANT OR RITUXIMAB-DEPENDENT NEPHROTIC SYNDROME AND IN PATIENTS INTOLERANT TO RITUXIMAB (THE ORION STUDY)

Not yet recruiting
2
20
Europe
GAZYVARO, OMNIPAQUE, [L01XC15], [Ioexolo], Concentrate and solvent for solution for infusion, Solution for injection, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Roche, IRCCS Istituto Mario Negri
PRIMARY MEMBRANOUS NEPHROPATHY Nefropatia membranosa primaria, PRIMARY MEMBRANOUS NEPHROPATHY Nefropatia membranosa primaria, Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
 
 
2019-004822-15: A Clinical Trial Examining the Effects of Temelimab Following Rituximab Treatment in Patients with Multiple Sclerosis

Not yet recruiting
2
40
Europe
Temelimab, GNbAC1, Solution for infusion
GeNeuro Innovation SAS, GeNeuro Innovation SAS
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
CTR20150541: A Phase II clinical study of AT-101 in the treatment of patients with chronic lymphocytic leukemia

Terminated
2
92
China
R-(-)-gossypol (AT 101) - Ascentage Pharma, Rituxan (rituximab) - Biogen, Zenyaku Holdings, Roche
Jiangsu Yasheng Pharmaceutical Development Co., Ltd.
Relapsed or refractory chronic lymphocytic leukemia (CLL)
 
 
2021-005861-41: A research study to evaluate the safety and effectiveness and dosing of Zilovertamab Vedotin with R-CHP in adults with DLBCL Un estudio en investigación para evaluar la seguridad y eficacia y la dosificación de Zilovertamab Vedotin con R-CHP en adultos con LDCBG.

Ongoing
2
60
Europe
zilovertamab vedotin, Endoxan, Doxorubicin-Ebewe, Prednisone, Truxima, MK-2140, Lyophilisate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, Tablet, Endoxan, Doxorubicin-Ebewe, Prednison 50 mg GALEN, Truxima
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Diffuse Large B-cell Lymphoma (DLBCL) Linfoma difuso de linfocitos B grandes (LDCBG), Phase II dose confirmation study in diffuse large B-cell lymphoma Estudio fase II de confirmación de dosis en Linfoma difuso de linfocitos B grandes., Diseases [C] - Cancer [C04]
 
 
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Active, not recruiting
2
33
US
Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan
PrECOG, LLC., Genentech, Inc.
Mantle Cell Lymphoma
10/22
11/24
NCT03620903 / 2017-004362-95: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Active, not recruiting
2
53
Europe
Ibrutinib / Bortezomib / Rituximab, Imbruvica / Velcade / Mabthera
Christian Buske, University of Ulm, ClinAssess GmbH, Zentrum für Klinische Studien Ulm, Hoffmann-La Roche, Johnson & Johnson
Waldenstrom Macroglobulinemia
11/22
09/29
ChiCTR2100044313: A single-arm, prospective, multi-center phase II clinical study of tislelizumab injection combined with R-CHOP in the treatment of primary mediastinal large B-cell lymphoma

Recruiting
2
20
China
tislelizumab injection combined with R-CHOP
Affiliated Tumor Hospital of Xinjiang Medical University ; Affiliated Tumor Hospital of Xinjiang Medical University, BeiGene (Shanghai) bio-pharmaceutical Co. , Ltd.
Primary mediastinal Large B-Cell Lymphoma.
 
 
PCR, NCT05115409: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL

Not yet recruiting
2
27
NA
Anti-PD-1 Antibody Plus Chidamide and Rituximab
Sun Yat-sen University, Chipscreen Biosciences, Ltd.
Relapsed or Refractory DLBCL
12/22
12/24
NCT04235036: Ibrutinib and Rituxan for Chronic GVHD

Terminated
2
19
US
Rituximab, Ibrutinib
Northside Hospital, Inc., Pharmacyclics LLC.
Graft Vs Host Disease
12/22
12/22
2019-001734-34: Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy.

Not yet recruiting
2
72
Europe
Rituximab, LNP023, Capsule, hard, Concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion
Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Idiopathic Membranous nephropathy, Kidney disease, Diseases [C] - Immune System Diseases [C20]
 
 
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms.

Not yet recruiting
2
150
Europe
Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV
Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04]
 
 
ZUMA-14, NCT04002401: Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Hourglass Mar 2021 - Dec 2021 : Initial data from ZUMA-14 trial for refractory DLBCL
Checkmark From ZUMA-14 trial in combination with either rituximab or lenalidomide for DLBCL at ASH 2019
Nov 2019 - Nov 2019: From ZUMA-14 trial in combination with either rituximab or lenalidomide for DLBCL at ASH 2019
Completed
2
27
US
Axicabtagene Ciloleucel, Yescarta®, Rituximab, RITUXAN®, Fludarabine, Cyclophosphamide
Kite, A Gilead Company
Refractory Large B-cell Lymphoma
01/23
01/23
CORAL, NCT05209308: Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Withdrawn
2
42
US
Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta
MEI Pharma, Inc., Kyowa Kirin, Inc.
CLL
03/23
03/23
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23
COMBIVAS, NCT03967925 / 2017-004645-24: Rituximab and Belimumab Combination Therapy in PR3 Vasculitis

Active, not recruiting
2
31
Europe
Belimumab, Benlysta, Rituximab, Truxima, Prednisolone, prednisone
Rachel Jones, GlaxoSmithKline, Medical Research Council, Imperial College London, University College, London, Newcastle University, University of Glasgow, University of Cambridge
ANCA Associated Vasculitis, Granulomatosis With Polyangiitis
04/23
11/23
NCT04375228: Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Recruiting
2
30
US
Rituximab, RITUXAN, Tocilizumab, ACTEMRA
Columbia University, Genentech, Inc.
Immune-related Adverse Events, Advanced Solid Tumor
05/24
05/25
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
CREDIT, NCT05093140: Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

Not yet recruiting
2
30
NA
Camrelizumab, Rituximab, Cyclophosphamide, Hydroxyldaunorubicin, Vincristine, Prednisone
Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.
Primary Extranodal Lymphoma, DLBCL
06/23
12/24
2019-004540-29: The effectivness and safety of ponatinib administered in combination with reduced chemotherapy in treatment of acute lymphoblastic leukemia in adults. Účinnost a bezpečnost ponatinibu podaného v kombinaci s redukovanou chemoterapií v léčbě akutní lymfoblastové leukémie dospělých

Not yet recruiting
2
32
RoW
cytarabine, cyclophosphamide, Dexamethasone, rituximab, vincristine, methotrexate, filgrastim, Film-coated tablet, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Injection, ICLUSIG 15 mg film-coated tablets
Ústav hematologie a krevní transfuze, Incyte Biosciences Distribution B.V., CZECRIN - Czech Clinical Research Infrastructure Network
NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA NOVĚ DIAGNOSTIKOVANÁ AKUTNÍ LYMFOBLASTOVÁ LEUKÉMIE S POZITIVITOU FILADELFSKÉHO CHROMOSOMU, Untreated Ph+ Acute Lymphoblastic Leukemia Neléčená Ph+ akutní lymfoblastová leukémie, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Recruiting
2
90
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
06/24
07/27
NCT02532257: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Completed
2
46
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Janssen, LP
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
08/23
08/23
NCT03995147: Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Recruiting
2
51
US
Pembrolizumab, R-CHOP Protocol, Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone
University of Chicago, Merck Sharp & Dohme LLC
B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
08/24
08/24
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
NCT02633137: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Completed
2
49
US
Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC)
Memorial Sloan Kettering Cancer Center, Celgene Corporation
Mantle Cell Lymphoma, Untreated
11/23
11/23
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
NCT03863184: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Lenalidomide and Rituximab for 1L MCL at ASH 2022
Active, not recruiting
2
35
US
Acalabrutinib, CALQUENCE, ACP-196, Lenalidomide, Revlimid, Rituximab, Rituxan
Weill Medical College of Cornell University, AstraZeneca, Celgene Corporation
Mantle Cell Lymphoma
09/24
09/27
VEGA, NCT05564052 / 2022-000364-21: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
36
Europe, US, RoW
Ibrutinib, JNJ-54179060, IMBRUVICA, PCI-32765, Lenalidomide, Rituximab, Bortezomib
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma, Mantle-Cell
12/23
09/24
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Recruiting
2
40
Europe
Glofitamab + Obinutuzumab
French Innovative Leukemia Organisation, Hoffmann-La Roche
Richter Syndrome
03/26
03/27
NCI-2023-08755, NCT06247540: Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Withdrawn
2
29
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Nivolumab, ABP 206, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Northwestern University, National Cancer Institute (NCI), Bristol-Myers Squibb, AbbVie
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
12/29
12/31
NCT00848328: Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
30
US
Rituximab, Rituxan, MabThera, Lenalidomide, REVLIMID
University of California, Davis, Celgene
Lymphoma
04/24
12/24
OSU-23307, NCT06390956: Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma

Not yet recruiting
2
23
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pirtobrutinib, 5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide, BTK Inhibitor LOXO-305, Jaypirca, LOXO 305, LOXO-305, LOXO305, LY3527727, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
Narendranath Epperla, Eli Lilly and Company
Marginal Zone Lymphoma
12/25
12/25
EpLCART, NCT06414148: MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Not yet recruiting
2
40
RoW
Epcoritamab, Epcoritamab, lenalidomide and rituximab
Peter MacCallum Cancer Centre, Australia, AbbVie
Relapsed/Refractory Large B-cell Lymphoma
10/26
05/28
BV mini CHP, NCT02734771: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting
2
24
US
Brentuximab vedotin, Adcetris, SGN-35, cAC10-vcMMAE, Rituximab, Rituxan, Mabthera, Cyclophosphamide, Cytoxan, Lyophilizedcytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin, Doxorubicin, Adriamycin, Doxil, Caelyx, Myocet, Prednisone, Deltasone, Orasone, Adasone, Deltacortisone, Prednisonum
Patrick Reagan, Seagen Inc.
Diffuse Large B-Cell Lymphoma
06/24
06/24
NCT03569995: [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

Recruiting
2
35
RoW
Rituximab, Truxima Inj, Methotrexate, Methotrexate Inj, Cytarabine Injection, Cytarabine
Won Seog Kim, Celltrion
Primary CNS Lymphoma
06/24
06/25
COPA-R-CHOP, NCT04263584: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

Active, not recruiting
2
62
Europe
Copanlisib, R-CHOP Chemotherapy
University Hospital Muenster, Bayer
Diffuse Large B Cell Lymphoma
04/25
04/25
NCT04416451: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Active, not recruiting
2
6
US
Rituximab, Venetoclax
Memorial Sloan Kettering Cancer Center, AbbVie
Marginal Zone Lymphoma
06/24
06/24
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Active, not recruiting
2
36
Europe
Copanlisib, Aliqopa, Rituximab, Truxima
Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer
Marginal Zone Lymphoma
06/24
12/29
NCT01316523: Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Active, not recruiting
2
30
US
Rituximab, Rituxan, Lenalidomide, Revlimid
University of California, Davis, Celgene
Non Hodgkin's Lymphoma
07/24
12/24
NCI-2018-02699, NCT03749018: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
2
30
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
David Bond, MD, Bristol-Myers Squibb
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Indolent Non-Hodgkin Lymphoma, Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
07/24
07/24
NCT04594798: A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Recruiting
2
39
US
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
University of Rochester, Genentech, Inc.
DLBCL, Lymphoma, B-Cell
07/24
07/24
NCT04998669: Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting
2
39
US
Loncastuximab tesirine, ADCT-402, Rituximab, Rituxan
Juan P. Alderuccio, MD, ADC Therapeutics S.A.
Follicular Lymphoma
08/24
08/27
GOLSEEK-2, NCT06425302: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Not yet recruiting
2
90
Europe, Canada, US, RoW
Golcadomide, CC-99282, BMS-986369, Rituximab, Mabthera, Cyclophosphamide, Endoxan, Doxorubicin, Caelyx, pegylated liposomal doxorubicin, PLD, Vincristine, Prednisone, Bendamustine
Celgene
Lymphoma, Follicular
11/26
11/28
NCT06388941: Iptacopan in Patients With ANCA Associated Vasculitis

Not yet recruiting
2
78
NA
Iptacopan, LNP023, Placebo, Rituximab
Novartis Pharmaceuticals
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
08/27
09/27
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting
2
30
RoW
Rituximab, lenalidomide, Truxima Inj, Lenalid
Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation
Primary CNS Lymphoma
11/24
11/24
NCT05156710 / 2021-000010-41: BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

Recruiting
2
45
Europe, Canada, US
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Sanofi, Sanofi-Aventis Recherche & Développement
Transplant Rejection
11/24
12/26
NCT03054896: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Recruiting
2
67
US
Venetoclax, Venclexta, DA-EPOCH-R, R-CHOP
Dana-Farber Cancer Institute, Genentech, Inc.
Richter Syndrome
12/24
12/27
BRAWM, NCT04624906: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Active, not recruiting
2
59
Canada
Acalabrutinib, Calquence, Bendamustine, Treanda, Rituximab, Rituxan
Sunnybrook Health Sciences Centre, AstraZeneca
Waldenstrom Macroglobulinemia
12/24
03/30
NCT01446133: Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Active, not recruiting
2
120
US
Rituximab, Rituxan, Lenalidomide, CC-5013, Revlimid
M.D. Anderson Cancer Center, Celgene Corporation
Leukemia, Lymphoma
12/24
12/24
NCT02251548: A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
85
US
Ibrutinib, Imbruvica™, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan®
Dana-Farber Cancer Institute, Pharmacyclics LLC., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia, Leukemia
01/25
01/26
NCT05376319: PR3-AAV Resilient Remission or PRRR

Terminated
2
6
US
Obinutuzumab, Rituximab
Mayo Clinic, Genentech, Inc.
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
05/24
05/24
NCT02339922: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Active, not recruiting
2
33
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Rituximab Biosimilar SIBP-02
University of Washington, Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
01/25
01/31
LOTIS-9, NCT05144009: A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Completed
2
41
Europe, US
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab
ADC Therapeutics S.A.
Diffuse Large B-cell Lymphoma
01/24
01/24
ORION, NCT05050214: Obinutuzumab in Primary MN

Active, not recruiting
2
20
Europe
Obinutuzumab, GAZYVA, GAZYVARO
Mario Negri Institute for Pharmacological Research, Roche Pharma AG
Membranous Nephropathy
04/25
04/25
GO43075, NCT04980222 / 2021-001647-28: A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
46
Europe, US
Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide
Hoffmann-La Roche
Lymphoma
06/25
06/25
NCT03844061: Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Recruiting
2
30
US
Belimumab, Benlysta, Rituximab, Rituxan, Placebo Subcutaneous Injection, Placebo Infusion, MMF, Cellcept, Mycophenolate Mofetil
Hospital for Special Surgery, New York, GlaxoSmithKline
Systemic Sclerosis
06/25
06/26
NCT05575973: Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
55
RoW
Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide
Jianfeng Zhou, CSPC Ouyi Pharmaceutical Co., Ltd.
Diffuse Large B-cell Lymphoma
07/25
10/25
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Recruiting
2
50
RoW
Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product
Li Zhiming, Antengene Corporation
DLBCL Germinal Center B-Cell Type
07/25
12/25
NCT04679012: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Recruiting
2
20
US
Polatuzumab Vedotin, Polivy, Rituximab, Rituxan, chimeric anti-CD20 monoclonal antibody, Etoposide, VP-16, VePesid, etopophos, toposar, Prednisone, Deltasone, Orasone, Paracort, Cortan, Cyclophosphamide, cytoxan, Hydroxydaunomycin, Doxorubicin Hydrochloride, Hydroxydoxorubicin Hydrochloride
Weill Medical College of Cornell University, Genentech, Inc.
Richter Syndrome, Chronic Lymphocytic Leukemia
09/25
09/26
NCT05453500: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting
2
30
US
Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, Leurocristine, VCR, Vincrystine
University of Washington, Incyte Corporation
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
09/25
09/30
NCT05025423: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Recruiting
2
40
US
Venetoclax Oral Tablet [Venclexta], rituximab infusion [Rituxan], Bendamustine infusion
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AbbVie
Mantle Cell Lymphoma
09/25
09/26
RENAL-F02, NCT06047171: Rescue of Nephrons With ALE.F02

Recruiting
2
80
Europe, RoW
ALE.F02, Rituximab, GlucoCorticoid, Cyclophosphamid, Placebo, Immunosuppressive Agents
Alentis Therapeutics AG
Glomerulonephritis Rapidly Progressive
09/25
09/25
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Active, not recruiting
2
124
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
REMoDL-A, NCT04546620: Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
453
Europe
R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, R-CHOP + acalabrutinib, Acalabrutinib
University Hospital Southampton NHS Foundation Trust, AstraZeneca
Diffuse Large B Cell Lymphoma
01/27
07/27
 

Download Options